Liposome application: problems and prospects

Abstract Liposomes are now in the marketplace as cosmeticeuticals and, more important, pharmaceuticals. Three major achievements of liposome application: steric stabilization, remote loading of drugs by pH and ion gradients, and lipoplexes based on complexes of cationic liposomes with anionic nucleic acids or proteins extended research toward liposome application and opened the way for development of a large spectrum of products. However, liposomology still faces major deficiencies including: lack of control over drug release rate; sufficient loading of drugs for which pH and ion gradients do not apply; lack of means to override biological barriers (i.e. skin, blood–brain barrier); therapeutically efficient active targeting; and for a broad spectrum of non-medical applications, cheaper suitable raw materials (lipids). Overcoming these deficiencies is the current challenge of research and development of liposome application.

[1]  J. Petriz,et al.  A novel strategy affords high-yield coupling of antibody to extremities of liposomal surface-grafted PEG chains. , 1999, Biochimica et biophysica acta.

[2]  Y. Barenholz,et al.  Development of liposomal anthracyclines: from basics to clinical applications. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[3]  D. Tzemach,et al.  Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes , 1999, Cancer.

[4]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[5]  P. Low,et al.  Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.

[6]  L. Pilarski,et al.  Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. , 2000, Biochimica et biophysica acta.

[7]  Y. Barenholz,et al.  Gelation of liposome interior A novel method for drug encapsulation , 1992, FEBS letters.

[8]  D. Tzemach,et al.  Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. , 1999, Anti-cancer drugs.

[9]  Y. Barenholz,et al.  Comparison of Different Commercially Available Cationic Lipid-Based Transfection Kits , 2000 .

[10]  Daniel Harries,et al.  Direct Evidence for Counterion Release upon Cationic Lipid−DNA Condensation , 2000 .

[11]  W. Oyen,et al.  Radiolabeled liposomes for scintigraphic imaging. , 2000, Progress in lipid research.

[12]  Samuel Zalipsky,et al.  Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol) , 1996, FEBS letters.

[13]  M. Stuart,et al.  Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. , 1995, Biochimica et biophysica acta.

[14]  Y. Barenholz,et al.  Lamellarity of cationic liposomes and mode of preparation of lipoplexes affect transfection efficiency. , 1999, Biochimica et biophysica acta.

[15]  Y. Quinn,et al.  New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. , 1999, Bioconjugate chemistry.

[16]  K. Fujimori,et al.  Barrier ' ' Microscopic Tumor Nodules : Consequences of a ' ' Binding Site An Analysis of Monoclonal Antibody Distribution in Updated , 2006 .

[17]  M. Bally,et al.  The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. , 1990, Chemistry and physics of lipids.

[18]  F. Szoka,et al.  How are Nucleic Acids Released in Cells from Cationic Lipid-Nucleic Acid Complexes? , 1996 .

[19]  Y. Barenholz,et al.  Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. , 2001, Biochimica et biophysica acta.

[20]  S. Clerc,et al.  A quantitative model for using acridine orange as a transmembrane pH gradient probe. , 1998, Analytical biochemistry.

[21]  P. Cullis,et al.  Structural and fusogenic properties of cationic liposomes in the presence of plasmid DNA. , 1997, Biophysical journal.

[22]  A. Gabizon,et al.  An Improved Method for in Vivo Tracing and Imaging of Liposomes Using a Gallium 67-Deferoxamine Complex , 1988 .

[23]  Y. Barenholz,et al.  Electrostatic and structural properties of complexes involving plasmid DNA and cationic lipids commonly used for gene delivery. , 1998, Biochimica et biophysica acta.

[24]  Y. Yarden,et al.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.

[25]  Y. Barenholz,et al.  Stability of liposomal doxorubicin formulations: Problems and prospects , 1993, Medicinal research reviews.

[26]  K. Jørgensen,et al.  Dynamical order and disorder in lipid bilayers. , 1994, Chemistry and physics of lipids.

[27]  G. Koning,et al.  Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells , 1999, British Journal of Cancer.

[28]  Novel synthetic phospholipid protects lipid bilayers against oxidation damage: role of hydration layer and bound water , 1997 .

[29]  A. Emili,et al.  Immunogenicity of immunoliposomes. , 1991, Immunology letters.

[30]  Y. Barenholz,et al.  Rational design of amphiphile-based drug carriers and sterically stabilized carriers , 1995 .

[31]  B. Goins,et al.  The use of scintigraphic imaging as a tool in the development of liposome formulations. , 2001, Progress in lipid research.

[32]  Y. Barenholz,et al.  Probing DNA-cationic lipid interactions with the fluorophore trimethylammonium diphenyl-hexatriene (TMADPH). , 1998, Biochimica et biophysica acta.

[33]  D. Tzemach,et al.  Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  Jay X. Tang,et al.  Hierarchical self-assembly of F-actin and cationic lipid complexes: stacked three-layer tubule networks. , 2000, Science.

[35]  Y. Barenholz,et al.  In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. , 1992, Biochimica et biophysica acta.

[36]  Y. Barenholz,et al.  Hydration of polyethylene glycol-grafted liposomes. , 1998, Biophysical journal.

[37]  Y. Barenholz,et al.  Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes. , 1994 .

[38]  Y. Barenholz,et al.  The Role of Hydration in Stabilization of Liposomes: Resistance to Oxidative Damage of PEG-Grafted Liposomes , 1998 .

[39]  D. Papahadjopoulos,et al.  Medical applications of liposomes , 1998 .

[40]  T. Reinheckel,et al.  Electrophoretic evidence for the impairment of complexes of the respiratory chain during iron/ascorbate induced peroxidation in isolated rat liver mitochondria. , 1995, Biochimica et biophysica acta.

[41]  Lasic Dd,et al.  Sterically stabilized liposomes in cancer therapy and gene delivery. , 1999 .

[42]  D. Harries,et al.  The phase behavior of cationic lipid-DNA complexes. , 2000, Biophysical journal.

[43]  D. Tzemach,et al.  Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. , 1999, Bioconjugate chemistry.

[44]  Y. Barenholz,et al.  Damage to liposomal lipids: protection by antioxidants and cholesterol-mediated dehydration. , 2000, Chemistry and physics of lipids.

[45]  D. Lasič LIPOSOMES in GENE DELIVERY , 1997 .

[46]  Y. Barenholz,et al.  Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. , 1993, Biochimica et biophysica acta.

[47]  N. Oku,et al.  Long-circulating liposomes. , 1994, Critical reviews in therapeutic drug carrier systems.

[48]  C. Benz,et al.  CHAPTER 4.7 – Targeting of sterically stabilized liposomes to cancers overexpressing HER2/neu proto-oncogene , 1998 .

[49]  Y. Barenholz,et al.  Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. , 1991, British Journal of Cancer.

[50]  P. Cullis,et al.  Nomenclature for synthetic gene delivery systems. , 1997, Human gene therapy.

[51]  T. Salditt,et al.  Phase diagram, stability, and overcharging of lamellar cationic lipid-DNA self-assembled complexes. , 1999, Biophysical journal.

[52]  G. Martiny-Baron,et al.  Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro. , 2000, Biochimica et biophysica acta.

[53]  Y. Barenholz CHAPTER 7.1 – Design of liposome-based drug carriers: From basic research to application as approved drugs , 1998 .

[54]  M S Newman,et al.  Immunogenicity and pharmacokinetic attributes of poly(ethylene glycol)-grafted immunoliposomes. , 1997, Biochimica et biophysica acta.

[55]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A. Janoff Liposomes: Rational Design , 1998 .

[57]  D Needham,et al.  A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. , 2000, Cancer research.